Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients

BACKGROUND: Although the addition of immune checkpoint inhibitors (ICIs) to platinum-doublet chemotherapy has improved the efficacy of first-line therapy in extensive-disease small cell lung cancer (SCLC) patients, the best treatment option for patients with recurrent SCLC has not yet been determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kushiro, Kohei, Watanabe, Satoshi, Goto, Yuka, Fujisaki, Toshiya, Yanagimura, Naohiro, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Tanaka, Tomohiro, Saida, Yu, Sato, Yusuke, Ota, Takeshi, Koshio, Jun, Hayashi, Yoshiki, Miyabayashi, Takao, Matsumoto, Naoya, Ichikawa, Kosuke, Koyama, Kenichi, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554694/
https://www.ncbi.nlm.nih.gov/pubmed/36248339
http://dx.doi.org/10.21037/tlcr-22-225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554694/
https://www.ncbi.nlm.nih.gov/pubmed/36248339
http://dx.doi.org/10.21037/tlcr-22-225

Ejemplares similares